研究单位：[1]Biotech Pharmaceutical Co., Ltd.[2]Study Chair:Junjie WangPeking University Third Hospital[3]the Air Force Medical University[4]The Second Affiliated Hospital of Dalian Medical University[5]First Affiliated Hospital Xi'an Jiaotong University[6]Ruijin Hospital[7]Henan Cancer Hospital[8]West China Second University Hospital[9]Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine.HeBei[10]Wuhan University Zhongnan Hospital[11]Xiangya Hospital of Central South University[12]The Second Norman Bethune Hospital of Jilin University[13]The Fourth Hospital of Hebei Medical University Hebei Tumor Hospital[14]Hunan Cancer Hospital[15]Hunan Cancer Hospital[16]Second Affiliated Hospital of Nanchang University[17]The Second Hospital of Hebei Medical University[18]Shengjing Hospital[19]First Hospital of China Medical University[20]The First Affiliated Hospital of Nanchang University[21]Shanxi Provincial Cancer Hospital[22]The First Affiliated Hospital of USTC (Anhui Provincial Hospital)[23]The First Affiliated Hospital of University of South China[24]Liaoning Cancer Hospital & Institute[25]Southern Medical University[26]The Affiliated Hospital of Inner Mongolia Medical University[27]Cancer Hospital Affiliated to Harbin Medical University[28]Guangxi Medical University Cancer Center[29]The First Affiliated Hospital of Xiamen University[30]Fujian Cancer Hospital[31]Peking University Cancer Hospital Inner Mongolia Hospital[32]First People's Hospital of Foshan[33]Shenzhen People's Hospital[34]LanZhou University[35]Affiliated Hospital of North Sichuan Medical College[36]Yunnan Cancer Hospital[37]Yantai Yuhuangding Hospital[38]Tianjin Cancer Hospital Airport Hospital[39]Shandong Cancer Hospital ＆ Institute[40]Jiangxi Maternal and Child Health Hospital[41]Affiliated Hospital of Hebei University[42]Peking University Cancer Hospital & Institute[43]Shanxi Province Cancer Hospital[44]Show fewer investigators
研究目的：
The purpose of this study is to evaluate the efficacy and safety of nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy versus placebo combined with concurrent chemoradiotherapy in patients with locally advanced cervical squamous cell carcinoma. The primary hypotheses are that nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival.
